we will be conducting 60-minute interviews with young adults to hear about social connections (in person and online) and cancer support on social media

The purpose of this study is to learn how having specific help over a period of time (financial navigation) can help reduce your distress related to the cost of cancer. You will complete a survey to see if you have financial distress. If you have financial distress, you will then fill out a few more surveys and be asked more details about your current financial situation to determine what programs could be helpful for you. The surveys can be completed in person, by email, or over the phone. The navigator can help you complete the surveys if needed. After that, depending on your needs, you will have 1-6 appointments with the financial navigator over a period of 2 weeks -4 months. Risks to you are small due to the educational nature of this study. They may include mild emotional distress while talking about your cancer and financial experiences. Benefits

Screening tool to collect broader demographic and clinical data. Enhance understanding of site specific and trial specific accrual barriers.

The purpose of this study is to collect evidence for or against the addition of olanzapine to standard nausea/vomiting prophylaxis in children receiving cyclophosphamide-based Bone Marrow Transplant conditioning. Its findings will be generalizable to children receiving other types of chemotherapy that have the potential to increase nausea/vomiting.

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.

The purpose of this study is to test the safety of the two study drugs, venetoclax and selinexor, and to find the highest dose of venetoclax and selinexor that can be given safely when it is combined with chemotherapy drugs (cytarabine or cytarabine and fludarabine). This study tests different doses of venetoclax and selinexor to see which dose is safer in children with leukemia.

The purpose of this study is to understand how your gut plays a role in how well CAR T cell therapy works. Your gut is home to bacteria, which we call the gut microbiome. The gut microbiome can send signals to your immune cells, which may impact how well and how long CAR T cell therapy will last. We can find out what type of bacteria are in your gut microbiome by studying your stool. We can understand more about the signals sent to the immune system by studying your blood. We will ask for stool and blood at the same time points throughout your treatment. We will study the identities and function of the bacteria and immune cells to understand more about how these signals work during CAR T cell treatment.

The purpose of this study is to create a registry that will collect clinical data from participants attending UNC Hospitals who may present with metastatic cancer and are evaluated to receive radiation therapy. We hope to create a registry that future studies can pull from to study the impacts of radiation therapy on patient cancer outcomes.

To create digital tools to support young adult cancer survivors completing active treatment and transitioning into survivorship care.